For the quarter ended December 2025, Alignment Healthcare (ALHC) reported revenue of $1.01 billion, up 44.4% over the same period last year. EPS came in at -$0.05, compared to -$0.16 in the year-ago quarter.
The reported revenue represents a surprise of +1.1% over the Zacks Consensus Estimate of $1 billion. With the consensus EPS estimate being -$0.15, the EPS surprise was +67.04%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Alignment Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Medical Benefit Ratio: 87.7% versus 89.1% estimated by five analysts on average.
- Health Plan Membership - Ending: 236,300 versus 233,752 estimated by four analysts on average.
- Revenues- Other: $9.01 million versus $10.57 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4.7% change.
- Revenues- Earned premiums: $1 billion versus $990.31 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +45.1% change.
View all Key Company Metrics for Alignment Healthcare here>>>
Shares of Alignment Healthcare have returned -8.8% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alignment Healthcare, Inc. (ALHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
